Rezolute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 51
- Market Cap
- $265.1M
- Website
- http://www.rezolutebio.com
- Introduction
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its clinical assets include Ersodetug, a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism, and RZ402, an oral plasma kallikrein inhibitor and potential therapy for the chronic treatment of diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for Hypoglycemia in Tumor Hyperinsulinism
Rezolute, Inc. announced FDA's Orphan Drug Designation for ersodetug, targeting hypoglycemia in tumor hyperinsulinism (HI), with a Phase 3 trial expected by 2025. Ersodetug, a monoclonal antibody, shows promise in treating HI by counteracting insulin receptor over-activation, offering potential universal treatment for hypoglycemia due to HI.
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Rezolute, Inc. announced FDA's Orphan Drug Designation for ersodetug, targeting hypoglycemia in tumor hyperinsulinism (HI), highlighting its potential universal treatment capability. The designation supports development for rare diseases, offering market exclusivity and expedited approval pathways. Ersodetug, a monoclonal antibody, shows promise in improving hypoglycemia by counteracting insulin receptor over-activation.
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Rezolute, Inc. announced FDA's Orphan Drug Designation for ersodetug, targeting hypoglycemia in tumor hyperinsulinism (HI), with a Phase 3 trial expected in 2025. Ersodetug, a monoclonal antibody, shows promise in treating HI by counteracting insulin receptor over-activation, offering potential universal treatment for hypoglycemia due to HI.
Rezolute's Hypoglycemia Drug Wins FDA Orphan Drug Designation
FDA granted Orphan Drug Designation to Rezolute’s ersodetug for treating hypoglycemia due to tumor hyperinsulinism, highlighting its potential universal effectiveness. A Phase 3 trial is set for 2025, with real-world benefits already observed. The designation supports development for rare diseases, offering market exclusivity and expedited approval pathways.
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug for Hypoglycemia in Tumor Hyperinsulinism
Rezolute, Inc. received FDA Orphan Drug Designation for ersodetug, targeting hypoglycemia in tumor hyperinsulinism (HI), highlighting its potential as a universal treatment. This designation supports development for rare diseases, offering market exclusivity and expedited approval pathways. Ersodetug, a monoclonal antibody, counters insulin receptor over-activation, showing promise in treating HI.
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for Treating Hypoglycemia Due to Tumor Hyperinsulinism
FDA granted Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for treating hypoglycemia due to tumor hyperinsulinism, highlighting its potential universal effectiveness. A Phase 3 trial is set for 2025, with real-world benefits already observed. The designation supports development for rare diseases, offering market exclusivity and expedited approval pathways.
Sidra Medicine conducts paediatric congenital hyperinsulinism trial
Sidra Medicine conducted the Phase III sunRIZE trial for paediatric congenital hyperinsulinism, led by Rezolute. The trial, approved by Qatar’s Ministry of Public Health, aims to develop a safer, non-invasive treatment option, reducing the need for surgery.
Sidra Medicine Successfully Conducts First Clinical Trial for Pediatric Congenital Hyperinsulinism
Sidra Medicine conducted Qatar's first industry-sponsored pediatric congenital hyperinsulinism trial, part of its Clinical Trials Program for rare diseases. The sunRIZE Phase 3 trial, led by Rezolute, aims to develop a non-invasive treatment for the condition, which causes life-threatening hypoglycemia in children. The trial was conducted on a three-month-old Qatari girl, marking a significant step in advancing care for congenital hyperinsulinism.
Sidra Medicine conducts first clinical trial for pediatric congenital hyperinsulinism
Sidra Medicine conducts Qatar's first industry-sponsored pediatric congenital hyperinsulinism trial, part of its Clinical Trials Program focusing on rare diseases. The sunRIZE Phase 3 trial, led by Rezolute, aims to develop a safer, non-invasive treatment, reducing the need for surgery in affected children.
Rezolute, Inc. - Innovating Therapies for Rare Diseases and Hyperinsulinism
A biopharmaceutical company focuses on creating therapies for rare diseases, emphasizing patient-centered decisions. It aims to combat hyperinsulinism's hypoglycemia across various patient groups, collaborating globally to restore life balance.
© Copyright 2025. All Rights Reserved by MedPath